

Cinipride

(C i n i t a p r i d e)

1mg Tablet & 1mg/5ml Syrup

TABLET

Composition

Each tablet contains:
Cinipride Hydrogen Tartrate
equivalent to Cinipride 1 mg.

SYRUP

Composition

Each 5 ml contains:
Cinipride Hydrogen Tartrate
equivalent to Cinipride 1 mg.

DESCRIPTION:

Cinipride is a prokinetic.

PHARMACOLOGICAL PROPERTIES:

Pharmacodynamics:

Cinipride is an orthopramide with gastrointestinal prokinetic activity, with considerable muscarinic properties. It blocks the presynaptic serotonin receptors and increases its release, resulting in greater serotonergic activity. Though it has discrete antidopaminergic activity, this adds to serotonergic therapeutic effect. In clinical trials conducted on patients and healthy individuals, Cinipride antagonized gastroparesis and vomiting induced by L-dopa. In a comparative study with placebo, Cinipride significantly accelerated gastric emptying in patients with a pathological delayed gastric emptying time. Cinipride improves the clinical symptoms of patients with dyspepsia associated with slow gastric emptying and delayed gastrointestinal transit. Cinipride reduces the number and duration of reflux episodes in patients with gastroesophageal reflux with an oesophageal pH of less than 4. In this case Cinipride's efficacy could be due not only to an increase in the pressure of the inferior oesophageal sphincter but also due to its prokinetic effect.

Pharmacokinetics:

Maximum plasma levels are reached two hours after the oral administration of Cinipride. Its elimination half-life is 3 to 5 hours for the first 8 hours, with a residual half-life of over 15 hours with extremely low plasma levels after that time. In view of this pharmacokinetic profile, the most advisable dosage regimen is three times a day. No accumulation has been observed after the repeated administration of Cinipride.

INDICATION:

CINIPRIDE is indicated in the treatment of gastroesophageal reflux and functional gastrointestinal motility disorders (slow gastric emptying).

DOSAGE AND ADMINISTRATION:

Adults (over 20 years of age)

1. Cinipride tablet, 3 times a day, 15 minutes before each meal.
2. Cinipride syrup 5ml, 3 times a day, 15 minutes before meals.

Do not exceed the recommended dose. Since there is no experience of its use in children and adolescents the administration of Cinipride is not advisable in this age group.

CONTRAINDICATIONS:

Cinipride should not be administered to patients with:

- Hemorrhages obstructions or perforations in whom stimulating gastric motility could be harmful.
- Proven tardive dyskinesia to neuroleptic drugs.

SPECIAL WARNINGS AND PRECAUTIONS:

Prolonged treatment with Cinipride can cause tardive dyskinesia in elderly patients. Cinipride can prolong cardiac repolarization in in-vitro studies with much higher concentrations than the plasma concentrations found in clinical practice. However, in-vivo studies in both animals and humans have shown no effect on electrocardiogram particularly on the QT interval.

سینیپرائیڈ

(سینیپرائیڈ)

۱ ٹیبلٹ / ۱۵ ملی لیٹر سیرپ

INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION:

The prokinetic activity of Cinipride can alter the absorption of some drugs. The patient must inform the doctor whether he/she is under treatment with other drugs. Cinipride can potentiate the effects of phenothiazine and other anti-dopaminergic drugs on the CNS. It can reduce the effect of digoxin by reducing its absorption. Anti-cholinergic drugs and opioid analgesics can reduce the effect of Cinipride on the digestive tract. Its sedative effects increases with co-administration with alcohol, tranquilizers, hypnotic or narcotic drugs.

PREGNANCY AND LACTATION:

Even though no teratogenic effects have been seen, Cinipride should not be administered in the first three months of pregnancy. Should its use be necessary, the physician must assess the risk / benefit ratio.

EFFECTS ON ABILITY TO DRIVE AND USE MACHINES:

Driving vehicles or using dangerous machines should be avoided during treatment with Cinipride.

ADVERSE EFFECTS:

Some patients may notice a slight sedation although Cinipride has not shown sedation or changes in the psychometric tests of subjects taking the recommended doses. On rare occasion there may be extra pyramidal effects with spasms in the muscles of the face, neck and tongue, which disappear when the treatment is stopped. The following may appear on very rare occasions.

- Skin reactions: rash, pruritus.
- Gynecomastia
- Very occasionally angioedema.

OVERDOSAGE:

Overdose may lead to sedation, disorientation and extrapyramidal effects, which normally disappear when the treatment is stopped. If the symptoms persist, gastric lavage should be performed and symptomatic treatment administered. For extrapyramidal symptoms anti-Parkinson, anticholinergic or antihistaminic drugs with anticholinergic properties should be given.

STORAGE:

- Store below 30°C in a dry place, protect from light.
- To be dispensed on the prescription of a registered medical practitioner only.
- Keep out of the reach of children.
- Keep bottle tightly closed.

PRESENTATION:

Cinipride 1 mg tablets available in blister pack of 10's & 30's tablets.
Cinipride Syrup is available in Bottle of 60ml & 120 ml.

خوراک: ڈاکٹر کی ہدایت کے مطابق استعمال کریں۔

ہدایات:

- دو کو ۳ ڈگری سینیٹری گریڈ سے کم درجہ حرارت پر روشنی سے بچا کر خشک جگہ پر رکھیں۔
- صرف رجسٹرڈ ڈاکٹر کے نسخے پر ہی فروخت کریں۔
- بچوں کی پہنچ سے دور رکھیں۔
- ڈھکن کو اچھی طرح بند رکھیں۔

Manufactured by:

Kaizen Pharmaceuticals (Pvt.) Ltd.
E-127-129, North Western Industrial Zone,
Bin Qasim, Karachi-75020, Pakistan.

ART No.: 045/4